AAAAAA

   
Results: 1-9 |
Results: 9
PHASE-1 TRIAL OF RECOMBINANT HUMAN INTERLEUKIN-1-BETA (RHIL-1-BETA), CARBOPLATIN, AND ETOPOSIDE IN PATIENTS WITH SOLID CANCERS - SOUTHWEST-ONCOLOGY-GROUP STUDY 8940
Authors: RINEHART J HERSH E ISSELL B TRIOZZI P BUHLES W NEIDHART J
Citation: J. Rinehart et al., PHASE-1 TRIAL OF RECOMBINANT HUMAN INTERLEUKIN-1-BETA (RHIL-1-BETA), CARBOPLATIN, AND ETOPOSIDE IN PATIENTS WITH SOLID CANCERS - SOUTHWEST-ONCOLOGY-GROUP STUDY 8940, Cancer investigation, 15(5), 1997, pp. 403-410
ORAL GANCICLOVIR FOR THE PREVENTION OF CYTOMEGALOVIRUS DISEASE IN PERSONS WITH AIDS
Authors: SPECTOR SA MCKINLEY GF LALEZARI JP SAMO T ANDRUCZK R FOLLANSBEE S SPARTI PD HAVLIR DV SIMPSON G BUHLES W WONG R STEMPIEN MJ
Citation: Sa. Spector et al., ORAL GANCICLOVIR FOR THE PREVENTION OF CYTOMEGALOVIRUS DISEASE IN PERSONS WITH AIDS, The New England journal of medicine, 334(23), 1996, pp. 1491-1497
POPULATION DIFFERENCES IN GANCICLOVIR CLEARANCE AS DETERMINED BY NONLINEAR MIXED-EFFECTS MODELING
Authors: YUEN GJ DRUSANO GL FLETCHER C CAPPARELLI E CONNOR JD LALEZARI JP DREW L FOLLANSBEE S BUSCH D JACOBSON M SPECTOR SA SQUIRES K BUHLES W
Citation: Gj. Yuen et al., POPULATION DIFFERENCES IN GANCICLOVIR CLEARANCE AS DETERMINED BY NONLINEAR MIXED-EFFECTS MODELING, Antimicrobial agents and chemotherapy, 39(10), 1995, pp. 2350-2352
ORAL GANCICLOVIR AS MAINTENANCE TREATMENT FOR CYTOMEGALOVIRUS RETINITIS IN PATIENTS WITH AIDS
Authors: DREW WL IVES D LALEZARI JP CRUMPACKER C FOLLANSBEE SE SPECTOR SA BENSON CA FRIEDBERG DN HUBBARD L STEMPIEN MJ SHADMAN A BUHLES W
Citation: Wl. Drew et al., ORAL GANCICLOVIR AS MAINTENANCE TREATMENT FOR CYTOMEGALOVIRUS RETINITIS IN PATIENTS WITH AIDS, The New England journal of medicine, 333(10), 1995, pp. 615-620
PHARMACOKINETIC, SAFETY, AND ANTIVIRAL PROFILES OF ORAL GANCICLOVIR IN PERSONS INFECTED WITH HUMAN-IMMUNODEFICIENCY-VIRUS - A PHASE I II STUDY/
Authors: SPECTOR SA BUSCH DF FOLLANSBEE S SQUIRES K LALEZARI JP JACOBSON MA CONNOR JD JUNG D SHADMAN A MASTRE B BUHLES W DREW WL DANKNER WM MEIXNER L FREEMAN WR DYNER TS FREEMAN E MORTILLARO G GLUTZER E BUSH T COLEMAN R
Citation: Sa. Spector et al., PHARMACOKINETIC, SAFETY, AND ANTIVIRAL PROFILES OF ORAL GANCICLOVIR IN PERSONS INFECTED WITH HUMAN-IMMUNODEFICIENCY-VIRUS - A PHASE I II STUDY/, The Journal of infectious diseases, 171(6), 1995, pp. 1431-1437
EXPOSURE PARAMETERS AND OUTCOME OF CMV RETINITIS FOR ORAL GANCICLOVIR
Authors: PLAISANCE K PISCITELLI DA YOUNG D BIGORA S PERDUE B KEAY S GAINES K JUNG D BUHLES W
Citation: K. Plaisance et al., EXPOSURE PARAMETERS AND OUTCOME OF CMV RETINITIS FOR ORAL GANCICLOVIR, Clinical pharmacology and therapeutics, 57(2), 1995, pp. 177-177
NONLINEAR MIXED EFFECTS MODELING (NONMEM) OF THE POPULATION PHARMACOKINETICS (PPK) OF ORAL GANCICLOVIR (GA)
Authors: PISCITELLI DA PLAISANCE K YOUNG D BIGORA S PERDUE B GAINES K JUNG D BUHLES W
Citation: Da. Piscitelli et al., NONLINEAR MIXED EFFECTS MODELING (NONMEM) OF THE POPULATION PHARMACOKINETICS (PPK) OF ORAL GANCICLOVIR (GA), Clinical pharmacology and therapeutics, 57(2), 1995, pp. 214-214
PHASE-I STUDY OF RECOMBINANT HUMAN INTERLEUKIN-1-BETA (RHIL-1-BETA) IN PATIENTS WITH BONE-MARROW FAILURE
Authors: NEMUNAITIS J ROSS M MEISENBERG B APPELBAUM FR BUHLES W SINGER J PETERS WP OREILLY R LILLEBY K BUCKNER CD
Citation: J. Nemunaitis et al., PHASE-I STUDY OF RECOMBINANT HUMAN INTERLEUKIN-1-BETA (RHIL-1-BETA) IN PATIENTS WITH BONE-MARROW FAILURE, Bone marrow transplantation, 14(4), 1994, pp. 583-588
A RANDOMIZED, CONTROLLED-STUDY OF INTRAVENOUS GANCICLOVIR THERAPY FORCYTOMEGALOVIRUS PERIPHERAL RETINITIS IN PATIENTS WITH AIDS
Authors: SPECTOR SA WEINGEIST T POLLARD RB DIETERICH DT SAMO T BENSON CA BUSCH DF FREEMAN WR MONTAGUE P KAPLAN HJ KELLERMAN L CRAGER M DEARMOND B BUHLES W FEINBERG J
Citation: Sa. Spector et al., A RANDOMIZED, CONTROLLED-STUDY OF INTRAVENOUS GANCICLOVIR THERAPY FORCYTOMEGALOVIRUS PERIPHERAL RETINITIS IN PATIENTS WITH AIDS, The Journal of infectious diseases, 168(3), 1993, pp. 557-563
Risultati: 1-9 |